Combination therapies against cancer targeting CD38 and TGF-β
AssigneeSanofi
InventorsFrancisco Adrian, Richard C. Gregory, Gary Shapiro, Helgi Van De Velde
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to combination cancer therapies targeting CD38 and TGF-β using antibodies specific for these targets. Also provided are compositions useful in the therapies.
Claims11
A method of treating a CD38-positive cancer in a human patient in need thereof, comprising administering to the patient
- an anti-CD38 antibody that has heavy chain CDR1 (HCDR1), HCDR2, HCDR3, light chain CDR1 (LCDR1), LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs:
- 15-20, respectively, and
- an anti-TGF-β antibody or an antigen-binding fragment thereof that has HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs:
- 5-10, respectively,
- wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
A method of treating a CD38-positive cancer in a human patient in need thereof, comprising administering to the patient an anti-CD38 antibody and an anti-TGF-β antibody or an antigen-binding fragment thereof, wherein the anti-CD38 antibody:
- a) has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs:
- 15-20, respectively;
- b) has a heavy chain variable domain (VH) and a light chain variable domain (VL) comprising the amino acid sequences of SEQ ID NOs:
- 13 and 14, respectively;
- or
- c) has a heavy chain (HC) and a light chain (LC) comprising the amino acid sequences of SEQ ID NOs:
- 11 and 12, respectively;
- and
- wherein the anti-TGF-β antibody:
- a) has HCDR1-3 and LCDR1-3 comprising the amino acid sequences of SEQ ID NOs:
- 5-10, respectively;
- b) has a VH and a VL comprising the amino acid sequences of SEQ ID NOs:
- 3 and 4, respectively;
- or
- c) has an HC and an LC comprising the amino acid sequences of SEQ ID NOs:
- 1 and 2, respectively,
- wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
A method of treating multiple myeloma in a human patient in need thereof, comprising administering to the patient an anti-CD38 antibody that comprises a heavy chain variable domain (VH) amino acid sequence of SEQ ID NO:
- 13 and a light chain variable domain (VL) amino acid sequence of SEQ ID NO:
- 14, and an anti-TGF-β antibody that comprises a VH amino acid sequence of SEQ ID NO:
- 3 and a VL amino acid sequence of SEQ ID NO:
- 4, wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
A method of treating multiple myeloma in a human patient in need thereof, comprising administering to the patient an anti-CD38 antibody that comprises a heavy chain (HC) amino acid sequence of SEQ ID NO:
- 11 and a light chain (LC) amino acid sequence of SEQ ID NO:
- 12, and an anti-TGF-β antibody that comprises an HC amino acid sequence of SEQ ID NO:
- 1 and an LC amino acid sequence of SEQ ID NO:
- 2, wherein the cancer is multiple myeloma that is refractory to treatment with Ab2, and the administering of the anti-CD38 antibody and the anti-TGF-β antibody or antigen-binding fragment slows cancer growth.
Dependencies are inferred from the claim text.